TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01333371

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Repair of Distal Radius Fracture
Description: 2 surgical methods to treat Distal Radius Fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Repair of Distal Radius Fracture
Description: 2 surgical methods to treat Distal Radius Fracture
Study: NCT03003949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release
Description: Transdermal Estradiol worn daily for 16 weeks (patch changed every 7 days).
Study: NCT01457924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3mg
Description: 3mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3mg
Description: 3mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3mg
Description: 3mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3mg
Description: 3mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 30mg
Description: 30mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 30mg
Description: 30mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 60mg
Description: 60mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 60mg
Description: 60mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 60mg
Description: 60mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 60mg
Description: 60mg of investigational product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00761553

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement without exercise
Description: Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
Study: NCT01457924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03419910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Specified dose on specified days
Study: NCT03926338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Neoadjuvant treatment with toripalimab plus celecoxib for 3 months
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) and Celecoxib (oral 200mg twice daily for 3 months) followed by surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: Neoadjuvant treatment with toripalimab monotherapy for 3 months
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 3 months) followed by surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Neoadjuvant treatment with toripalimab plus celecoxib for 6 months
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) and Celecoxib (oral 200mg twice daily for 6 months) followed by surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: Neoadjuvant treatment with toripalimab monotherapy for 6 months
Description: Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 months) followed by surgical resection.
Study: NCT00724815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP101 - Sumatriptan iontophoretic transdermal patch
Description: Sumatriptan iontophoretic transdermal patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NP101 Placebo iontophoretic transdermal patch
Study: NCT03345992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
Study: NCT03003949

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Matching placebo patches to be worn every day for 16 weeks (patch changed every 7 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Capsule
Description: Micronized progesterone (200 mg) will be administered every day for 12 days during the 9th week of randomization and again following randomization at the 17th week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Matching placebo capsules will be administered orally every day for 12 days during the 9th week of randomization and again following randomization at the 17th week.
Study: NCT03345992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Water for injection
Description: Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
Study: NCT01966861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weaning guided by LUS (lung ultrasound)
Description: Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score \>14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required \[CPIS\>6\], hemglobin\>8g/dl triggers transfusion)
Study: NCT01967472

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine-artesunate (AQAS) fixed-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination (AL) dispersable
Study: NCT00929045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Replacement
Study: NCT04902768

Intervention type: OTHER
Intervention: This is an observational study, there is no intervention
Description: This is an observational study, there is no intervention. Hence, this is not applicable.
Study: NCT03366818

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thrombectomy
Description: mechanical thrombectomy
Study: NCT01990703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Description: Timing of IUD insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel IUD
Description: Timing of IUD insertion
Study: NCT00832481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repaglinide
Description: Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
Study: NCT02140892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: respiratory physical therapy manual technique- Autogenic Drainage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: respiratory physical therapy technique- IPV
Study: NCT05018637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ-MSC
Description: Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.~Other: intramedullary injection of 4 x 107 WJ-MSCs (direct injection into the recently fractured vertebra) at baseline (day 0). subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.
Study: NCT00443846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq®
Description: Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq®
Description: Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C®
Description: Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-C®
Description: Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
Study: NCT02988492

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI perfusion imaging
Description: Evaluate the sensitivity and specificity of whole---brain CTP in predicting 24 hour DWI---MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
Study: NCT03261141

Intervention type: COMBINATION_PRODUCT
Intervention: (PV-RQOL),(APA) ,Acoustic analysis
Description: 1. severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL).

Intervention type: COMBINATION_PRODUCT
Intervention: (PV-RQOL),(APA) ,Acoustic analysis
Description: 1. severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~2. Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~3. the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL).
Study: NCT01639391

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: biopsy 5mm maximum on healthy skin under local anaesthesia.
Study: NCT01800851

Intervention type: OTHER
Group type: OTHER
Intervention: Energy expenditure evaluation in calorimetric chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy expenditure evaluation in calorimetric chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy expenditure evaluation in calorimetric chamber
Study: NCT02992873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Layperson allocated to start CPR and fetch nearest AED
Description: Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Layperson allocated to start CPR
Description: Dispatching laypersons to start CPR out-of-hospital cardiac arrest
Study: NCT04225390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC)
Description: Dacarbazine powder for IV solution
Study: NCT01570608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection 3 monthly injections thereafter as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection 3 monthly injections thereafter as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin
Description: Verteporfin photodynamic therapy standard fluence
Study: NCT02334553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1226(8%)
Description: The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
Study: NCT01831804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off-white smooth ointment for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off-white smooth ointment for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off-white smooth ointment for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off-white smooth ointment for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off-white smooth ointment for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off-white smooth ointment for topical application as single or repeat doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: White to off-white smooth ointment for topical application as single or repeat doses.
Study: NCT00493467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibritumomab Tiuxetan (Zevalin)
Description: 111In Zevalin (5 mCi of \^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8.
Study: NCT04649021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection
Study: NCT00493467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m\^2 Intravenously Over 4-6 Hours On Days 1 and 8.
Study: NCT06154499

Intervention type: PROCEDURE
Intervention: Radical prostatectomy
Description: Radical Prostatectomy: surgery to remove the prostate gland and seminal vesicles (and sometimes nearby lymph nodes) after a prostate cancer diagnosis
Study: NCT01258517

Intervention type: DEVICE
Intervention: near infrared spectroscopy (INVOS 5100)
Description: monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
Study: NCT03720301

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulation Treatment
Description: All techniques with patient supine and physician at head of the bed:~1. Soft tissue massage to the posterior cervical musculature for approximately 1 minute~2. Muscle energy to the muscles of neck extension approximately 1 minute~3. Muscle energy to the Occipital Atlanto (OA) joint 1 minute~4. Muscle energy to the jaw. Approximately 1 minute~5. Occipital decompression approximately 1 minute~6. With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~1. Myofascial Steering wheel Technique~2. Sibson's Fascia Release~3. Occipital decompression

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment.
Study: NCT04535206

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood collecting and test and ultrasound screening
Description: To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood collecting and test and ultrasound screening
Description: To collect the venous blood samples before the PICC catheterization, and perform ultrasound examination before and after the catheterization at the specified time point in follow-up.
Study: NCT03790150

Intervention type: OTHER
Intervention: Evidence-based practices
Description: Implementation of evidence-based practices
Study: NCT02843919

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography and Electrocardiography
Study: NCT01605383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XCEL-MT-OSTEO-ALPHA
Description: Core decompression plus XCEL-MT-OSTEO-ALPHA

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Isolated core decompression
Study: NCT02135900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heliox
Description: From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
Study: NCT02755025

Intervention type: OTHER
Intervention: Automated SOFA scoring calculator
Description: Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
Study: NCT03245502

Intervention type: BIOLOGICAL
Intervention: Blood transfusion
Description: The transfusion of erythrocyte suspension
Study: NCT04228887

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Strength
Description: Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Muscle Strength
Description: Respiratory muscle strengths will evalueted with inspiratory and expiratory mouth pressure devices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance training will provide with Biodex® Balance Training System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Balance training will provide with Biodex® Balance Training System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: 15 minutes twice a day, 5 times a week for 8 week with Threshold IMT device
Study: NCT02465255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study: NCT03509623

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling through direct peripheral venous puncture
Description: Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
Study: NCT02851368

Intervention type: DEVICE
Group type: OTHER
Intervention: near infrared fluorescence imaging (NIFI)
Description: The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green
Description: Indocyanine Green will be administered intravenously 1 day prior to NIFI.
Study: NCT02479438

Intervention type: OTHER
Intervention: Diagnosed with GERD
Description: Recording of patient outcomes
Study: NCT00844142

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept 25mg
Description: patients will receive etanercept 25mg twice weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
Study: NCT02588417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: levobupivacaine 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: levobupivacaine 2.5 mg
Study: NCT01582009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies